Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2018
At a glance
- Drugs Methotrexate (Primary) ; Regorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Aug 2018 Status changed from not yet recruiting to recruiting.
- 17 May 2018 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
- 17 May 2018 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.